Bionano Genomics, INC 8-K filings

Bionano Genomics has appointed former foundational team member Dr. Alex Hastie as its new Chief Scientific Officer, effective July 20, 2026.

Bionano Genomics, Inc. announced that Chief Medical Officer Alka Chaubey, Ph.D. will resign from her position effective July 5, 2026.

Bionano Genomics has fully repaid its $20 million in outstanding senior secured convertible debentures, eliminating all associated liens and restrictive covenants.

Bionano Genomics, Inc. reported on its 2026 Annual Meeting of Stockholders, detailing director elections, executive compensation advisory vote, and ratification of its independent auditor.

Bionano Genomics announced its first quarter 2026 financial results, reporting a 4% increase in total revenue to $6.7 million, driven by a 20% rise in consumables revenue.

Bionano Genomics has appointed Albert A. Luderer, Ph.D. as Interim CEO following the immediate termination of R. Erik Holmlin, Ph.D., effective May 5, 2026.

Bionano Genomics reported a slight revenue decrease for Q4 and full-year 2025, alongside improved gross margins and reduced operating expenses, while providing 2026 revenue guidance.

Bionano Genomics reported preliminary Q4 and full-year 2025 financial results, highlighting OGM adoption and reimbursement progress despite a year-over-year revenue decrease.

Bionano Genomics reported a 21% increase in third-quarter 2025 revenue to $7.4 million, alongside significant improvements in gross margin and reduced operating expenses, validating its strategic shift.

Bionano Genomics, Inc. successfully closed a public offering raising approximately $10 million in gross proceeds through shares and warrants to fund working capital and general corporate purposes.

Bionano Genomics reported a 52% gross margin and reduced operating expenses by 42% in Q2 2025, despite a 13% revenue decrease.

Bionano Genomics, Inc. filed an amendment to its recent 8-K report to correct previously reported shareholder voting results for the ratification of its accounting firm and the approval of common stock issuance related to warrants.

Bionano Genomics, Inc. reported the outcomes of its 2025 Annual Meeting of Stockholders, including the election of directors, approval of executive compensation, ratification of its independent auditor, and the crucial approval for the issuance of shares related to purchase warrants, alongside a new appointment to its Audit Committee.

Bionano Genomics reports a decrease in revenue for Q1 2025, but highlights progress in gross margin improvement and cost reduction efforts.

Bionano Genomics reports a decrease in revenue for Q4 and full-year 2024, but highlights cost reduction efforts and provides a revenue outlook for 2025.

Bionano Genomics has entered into an agreement with H.C. Wainwright & Co. to sell up to $75 million of its common stock through an at-the-market offering.

Bionano Genomics terminated its $200 million sales agreement with Cowen and Company, LLC, effective February 14, 2025.

Bionano Genomics executed a 1-for-60 reverse stock split, effective January 24, 2025, to increase its stock price and maintain Nasdaq compliance.

Bionano Genomics' stockholders approved the issuance of shares upon warrant exercises and a reverse stock split at a ratio between 1-for-25 and 1-for-75.

Bionano Genomics announced preliminary unaudited results for Q4 and full-year 2024, showing a revenue decrease due to the discontinuation of clinical service products, but also highlighting progress in OGM adoption and cost reduction efforts.

Bionano Genomics has entered into an agreement for a $10 million registered direct offering of common stock and warrants.

Bionano Genomics has amended its senior secured convertible debentures, deferring a December payment and modifying future redemption terms to improve its cash runway.

Bionano Genomics stockholders approved the issuance of up to 35,026,272 shares of common stock upon the exercise of certain warrants at a special meeting held on November 27, 2024.

Bionano Genomics reported a 35% decrease in revenue for Q3 2024 compared to the same period last year, alongside a reduction in cash burn due to restructuring.

Bionano Genomics has entered into a definitive agreement for a registered direct offering to raise approximately $3 million through the sale of common stock and warrants.

Bionano Genomics reports preliminary Q3 2024 revenue between $6.5 and $6.8 million, down from previous guidance of $7.9 to $8.9 million, alongside a strategic shift towards driving utilization of existing systems.

Bionano Genomics is implementing a reorganization plan involving a 45% workforce reduction and a change in financial leadership to cut costs and focus on existing customers.

Bionano Genomics reported a 10% decrease in revenue for Q2 2024 compared to Q2 2023, but saw a 29% increase in the installed base of its optical genome mapping (OGM) systems.

Bionano Genomics received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.

Bionano Genomics has announced a registered direct offering priced at-the-market, potentially raising up to $30 million through the sale of common stock and warrants.